New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Emergent BioSolutions Inc.
EBS
Shape
US Flag

NYSE

Unprofitable

Unprofitable

482M

Drug Manufacturers - Specialty & Generic

Next Earning date - 06 Nov 2024

482M

Drug Manufacturers - Specialty & Generic

Next Earning date - 06 Nov 2024

8.93USD
Shape-0.13 ( -1.43%)
favorite-chart

Relative Strenght

85
favorite-chart

Volume Buzz

-71%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

41%

Quote Panel

Shape
Updated October 26, 2024
1W -12.08 % 1M 19.49 % 3M -39.40 % 1Y 347.50 %

Key Metrics

Shape
  • Market Cap

    482.40M


  • Shares Outstanding

    54.02M


  • Share in Float

    51.91M


  • Dividende

    0


  • Earning Date

    06 Nov 2024


  • Price Target

    8.93


  • Average Volume

    2.75M


  • Beta

    1.592


  • Range

    1.42-15.1


  • Industry

    Drug Manufacturers - Specialty & Generic


  • Website

    https://www.emergentbiosolutions.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

0.44x

P/S Ratio

1.22x

P/B Ratio

2.2

Debt/Equity

-53.5%

Net Margin

$-11.2

EPS

How EBS compares to sector?

P/E Ratio

Relative Strength

Shape

EBS

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$1B

Shape370%

2025-Revenue

$0.92

Shape117%

2025-EPS

$186M

Shape243%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Rodman & Renshaw

initialise

Previous: Not converted

2024-08-22

Now: Buy

Benchmark

upgrade

Previous: Positive

2024-03-07

Now: Buy

Benchmark

upgrade

Previous: Hold

2023-04-10

Now: Positive

Benchmark

downgrade

Previous: Not converted

2022-11-10

Now: Hold

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-1.27
vs -0.36

Q4.22

arrow
arrow

N/A

-0.31
vs 4.5

Q1.23

arrow
arrow

N/A

-3.17
vs 0.18

Q2.23

arrow
arrow

N/A

-1.06
vs -0.86

Q3.23

arrow
arrow

N/A

-1.44
vs -1.27

Q4.23

arrow
arrow

N/A

-0.77
vs -0.31

Q1.24

arrow
arrow

+119%

0.59
vs -3.17

Q2.24

arrow
arrow

N/A

-2.32
vs -1.06

Q3.24

arrow
arrow

+107%

0.1
vs -1.44

Q4.24

arrow
arrow

N/A

-0.15
vs -0.77

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-27%

240M  vs 329M

Q4.22

arrow
arrow

-54%

330.7M  vs 723.2M

Q1.23

arrow
arrow

-46%

165.1M  vs 307.5M

Q2.23

arrow
arrow

+39%

337.9M  vs 242.7M

Q3.23

arrow
arrow

+13%

270.5M  vs 240M

Q4.23

arrow
arrow

-16%

276.6M  vs 330.7M

Q1.24

arrow
arrow

+82%

300.4M  vs 165.1M

Q2.24

arrow
arrow

-25%

254.7M  vs 337.9M

Q3.24

arrow
arrow

+7%

290.3M  vs 270.5M

Q4.24

arrow
arrow

-5%

262M  vs 276.6M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-5%

-0.05
vs -0.04

Q4.22

arrow
arrow

-6%

-0.06
vs -0.05

Q1.23

arrow
arrow

-15%

-0.15
vs -0.06

Q2.23

arrow
arrow

-27%

-0.27
vs -0.15

Q3.23

arrow
arrow

-38%

-0.38
vs -0.27

Q4.23

arrow
arrow

-8%

-0.08
vs -0.38

Q1.24

arrow
arrow

+1%

0.01
vs -0.08

Q2.24

arrow
arrow

-73%

-0.73
vs 0.01

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

207

207
vs 232

-11%

Q4.22

arrow
arrow

201

201
vs 207

-3%

Q1.23

arrow
arrow

195

195
vs 201

-3%

Q2.23

arrow
arrow

190

190
vs 195

-3%

Q3.23

arrow
arrow

166

166
vs 190

-13%

Q4.23

arrow
arrow

139

139
vs 166

-16%

Q1.24

arrow
arrow

126

126
vs 139

-9%

Q2.24

arrow
arrow

139

139
vs 126

10%

Earnings Growth

Latest News